| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_CDYL_0006500 | Intron-Exon-Intron | chr6:4891947-4912360 | chr6:4891713-4912126 | 115 nt | 0.3391 |
| hsa_CDYL_0006600 | Intron-Exon-Intron | chr6:4891947-4912744 | chr6:4891713-4912510 | 164 nt | 0.5854 |
| hsa_CDYL_0006700 | Intron-Exon-Intron | chr6:4891947-4924979 | chr6:4891713-4924745 | 94 nt | 0.3723 |
| hsa_CDYL_0005900 | Exon-Exon | chr6:4891947-4943990 | chr6:4891713-4943756 | 1308 nt | 0.4985 |
| hsa_CDYL_0006800 | Exon-Exon | chr6:4891955-4892613 | chr6:4891721-4892379 | 659 nt | 0.5432 |
| hsa_chr6_0550700 | Intergenic-Intergenic | chr6:4891965-4892324 | chr6:4891731-4892090 | 360 nt | 0.4889 |
| hsa_CDYL_0006900 | Exon-Exon | chr6:4891984-4892613 | chr6:4891750-4892379 | 630 nt | 0.5571 |
| hsa_chr6_0550800 | Intergenic-Intergenic | chr6:4891991-4892324 | chr6:4891757-4892090 | 334 nt | 0.5060 |
| hsa_CDYL_0007000 | Exon-Exon | chr6:4892014-4892337 | chr6:4891780-4892103 | 324 nt | 0.5123 |
| hsa_chr6_0550900 | Intergenic-Intergenic | chr6:4892144-4892324 | chr6:4891910-4892090 | 181 nt | 0.4917 |
A study in humans demonstrated that the circCDYL is highly expressed in early stages of hepatocellular carcinoma, bladder cancers, and breast cancer [Misir et al. DOI:10.1038/s41418-022-00948-7]. In hepatocellular carcinoma, it promotes stem-like characteristics and tumor growth via the miR-328-3p/HIF1AN axis under hypoxic conditions [Huang et al. DOI:10.3390/cells11091381]. A study in mice demonstrated that the circCDYL is decreased in myocardial tissues and hypoxia myocardial cells, where it improves cardiac function after acute myocardial infarction [Sema Misir et al. DOI:10.1038/s41418-022-00948-7].